Presentations: South Africa’s HIV, TB investment case
Experts’ presentations on South Africa’s HIV “investment case” made at a July consultation organised by the country’s national AIDS council.
Countries like Zimbabwe and Malawi have gone on to formulate national investment cases broadly guided by this document.
On 30 July 2014, the South African National AIDS Council (SANAC) convened a consultation to review the country’s investment framework. Below are three experts’ presentations.
Eva Kiwango, UNAIDS senior strategic information advisor
Although Kiwango cites the gains made by South Africa, she notes that challenges remain including early sexual debut, high loss to follow up among antiretroviral patients and structural drivers fueling new infections among women. She adds that the country’s investment framework could have important impacts for the formulation of domestic budgets including the medium term expenditure framework, HIV conditional grant and provincial equitable share formulation.
Download Kiwango’s presentation: Kiwango Investment Case Background_30 July 2014
Dr Gesine Meyer-Rath, Health Economics and Epidemiology Research Office
Previously, Meyer-Rath helped produce one of the country’s first detailed costings supporting the government’s move to early HIV treatment at a higher CD4 count of 350. In this presentation, she discusses the analytical framework for an investment case and possible data sources.
Download Meyer-Rath’s presentation: Meyer-Rath Investment Case 30 July
The final presentation outlines possible factors that may enable a better HIV and tuberculosis response in South Africa as well as technical efficiencies to be gained and possible challenges by sector.
Download the final presentation: Final SANAC Investment Framework Feedback 31 July